Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Pfizer Sells 49% Stake in China-Hisun Generic Drug JV

publication date: Nov 13, 2017

Pfizer has sold its 49% stake in a China generic drug JV it formed five years ago with Zhejiang Hisun Pharma. The company sold the stake to Sapphire I Holdings at an undisclosed price. In 2016, Pfizer signaled it intended to end the partnership because the JV's profits had not lived up to expectations. In 2012, when the JV was formed, it was said to be worth $545 million, with both companies contributing assets to the JV, not cash. More details....

Stock Symbols: (NYSE: PFE) (SHA: 600267)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.